Plazomicin Sulfate

Increasing Calprotrectin Serum Immunoassay Application in Inflammatory Bowel Disorders Diagnosis to Facilitate Growth A recent study conducted by Fact.MR presents a deep-dive assessment of the current dynamics affecting the pace of the calprotectin serum immunoassay market growth. The report also reveals insights into calprotectin serum immunoassay demand outlook in terms of assay type, application, and end user between 2021 and 2031 Fact.MR – A Market Research and Competitive Intelligence Provider: As per a survey by Fact.MR, the global calprotectin serum immunoassay market is poised to witness a steady growth during the forecast period 2021 to 2031. Increasing applications of calprotectin serum as inflammation marker is likely to create growth prospects for the market. Various researches are finding calprotectin serum immunoassay applications in diagnosis of numerous diseases like pulmonary fibrosis, cardio vascular diseases, and others. According to a study published in British Medical Journal (BMJ) and Bentham Science Publishers, a rise in of calprotectin serum was observed in the patients suffering from pulmonary fibrosis, aortic aneurysm, and rheumatoid arthritis diseases. Thus, administering immunoassays for detecting the serum for the diagnosis of these diseases is expected to elevate the market growth. Request a report brochure to gain comprehensive insights at Rising prevalence for inflammatory bowel disorders (IBDs) like Crohn disease and ulcerative colitis are the chief drivers, accelerating the market growth. According to a study report by the Crohn’s and Colitis Foundation of America, around 1.4 million people across the U.S. are affected by Crohn disease every year, with most of the patient diagnosed are under 30 years of age. As calprotectin serum immunoassay finds large applications in IBDs, increasing incidence of these disease will bolster the market growth. “Researchers are studying neutrophils, D-dimers, and fibrinogens extracted from calprotectin serum for determining the severity of the viral infection in coronavirus positive patients. This novel calprotectin serum application as biomarker for COVID19 will favor the market growth,” says the Fact.MR analyst. Key Takeaways from Fact.MR’s Calprotectin Serum Immunoassay Market Survey The U.S. is expected to emerge as the most lucrative market in North America, owing to the presence of leading market players such as Agilent Technologies, Inc. and Thermo-Fisher Scientific. The U.K. is estimated to exhibit steady growth, driven by the increasing number of research and development activities in the calprotectin serum immunoassay domain. Due to the high prevalence of inflammatory bowel disorders such as ulcerative colitis, the China market is forecast to a hold a significant revenue share in Asia Pacific. Based on end user, diagnostic laboratories are anticipated to account for a major share in the segment, supported by the increasing demand for effective diagnostic of rheumatoid arthritis and cardiovascular diseases. Key Drivers Growing awareness regarding the diagnostic testing for cardiovascular disease amongst the European population is expected to drive the market. Increasing applications in prevention and treatment of inflammatory bowel disorders will spur the sales of calprotectin serum immunoassay. Surging research and development activates for understanding the constant mutation of COVID-19 virus is estimated to propel the demand for calprotectin serum immunoassay Key Restraints High cost of equipment required for the calprotectin serum immunoassay is hampering the market growth. Lack of awareness regarding the application of calprotectin serum immunoassay across developing and under developed economies such as Thailand, Bhutan, and others is impeding the growth. To gain in-depth insights on Calprotectin Serum Immunoassay Market, request methodology at Competitive Landscape Companies operating in the market are focusing of adopting strategies such as product launch to expand their product portfolio and strategic merger, acquisition, and partnership to increase their market revenue share. For instance, In December 2018, Thermo Fisher Scientific, an American provisioner of scientific instrumentation, reagents and consumables, announced launching in new product, QMS Plazomicin Immunoassay, the world’s first complementary diagnostics immunoassay that measures the concentration of a new therapeutic antibiotic named Plazomicin. In February 2021, Agilent Technologies Inc., an American analytical instrumentation development and manufacturing company, announced launching the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit. It is capable of qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human calprotectin serum or plasma. Some of the leading players in the market profiled by Fact.MR are: Eurospital Calpro Thermo-Fisher Scientific Buehlmann Biotec Abbott Laboratories F.Hoffmann-La Roche Siemens AG Danaher Corporation Diasorin SPA Sysmex Corporation Biomerieux SA QIAGEN Agilent Technologies, Inc. More Valuable Insights on Calprotectin Serum Immunoassay Market Fact.MR, in its new report, offers an unbiased analysis of the global calprotectin serum immunoassay market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in calprotectin serum immunoassay market with detailed segmentation: By Assay Type: ELISA (Enzyme linked Immunosorbent Assay) Enzyme fluoroimmunoassay Quantitative immune-chromatography By Application: Crohn Disease Ulcerative colitis By End User: Hospitals Diagnostic Laboratories Ambulatory Care Centres Research Institutions By Region: North America Latin America Europe South Asia East Asia Oceania Middle East & Africa Key Questions Covered in the Calprotectin Serum Immunoassay Market Report The market survey also highlights projected sales growth for calprotectin serum immunoassay market between 2021 and 2031 The report offers insight into calprotectin serum immunoassay demand outlook for 2021-2031 Calprotectin serum immunoassay market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, collaborations or partnerships, and others Calprotectin serum immunoassay market analysis identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry Explore Fact.MR’s Coverage on the Healthcare Domain – Chemiluminescence Immunoassay (CLIA) Analyzers Market- Antibodies are increasingly being labelled using chemiluminescence immunoassay (CLIA) technology in laboratories all around the world. Chemiluminescent techniques are crucial in biomedical research. The number of clinical tests utilizing CLIA techniques is expected to grow as a result of technical advancements in disease diagnostics and increased need for preventive diagnostics and treatment monitoring. The global chemiluminescence immunoassay market is expected to grow positively as a result of these factors. Immunoassay Market- The database of biomarkers utilized by industry participants to design new assays that detect the onset of a disease or ailment has grown as a result of rapid advances in genomes and proteomics. The global immunoassays market is expected to grow at a rapid pace. With the growing database on genetics and biomarkers of numerous infectious pathogens, key firms are investing in the development of innovative immunoassays in the infectious diseases area. For the diagnosis of infectious disorders, immunoassay analyzers such as enzyme-linked immunosorbent assay (ELISA) and others are preferred. Laboratory Centrifuge Market- Over the last decade, laboratory centrifuges have grown in popularity across a wide range of industries, including pharmaceuticals, biotechnology, and microbiology. They are essential in the study and research of cells, macromolecules, and other disciplines of life science because of their ability to separate mixtures based on density and viscosity. Despite problems during the COVID-19 pandemic, laboratory centrifuge manufacturers are expected to gain traction as end customers like as academic and research institutes, hospitals, and diagnostic sectors continue to recover. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Source: Fact.MR

European Pharmaceutical Manufacturer editor Reece Armstrong looks at the antibiotics landscape and why we need to speak up about antimicrobial resistance (AMR). In April this year, as the Covid-19 pandemic continued to dominate headlines across global media channels, the World Health Organisation (WHO) published its latest annual review evaluating the current clinical and preclinical pipelines for antibacterial candidates. Conclusions from the report were stark, with WHO assistant director general on antimicrobial resistance (AMR), Dr Hanan Balkhy, saying that AMR is being fuelled by “the persistent failure to develop, manufacture, and distribute effective new antibiotics.” A month prior, The Pew Trusts in the US updated its findings on the global pipeline of antibiotics and the conclusions were similar. With 43 antibiotics in clinical development - with some inevitably failing to win approval – it’s obvious that there are too few therapies in development to tackle the growing threat of AMR. Of particular concern is how the larger pharmaceutical companies have completely taken themselves out of the picture when it comes to antibiotics. The Pew Trusts’ report says that of the 38 companies currently developing antibiotics, only two are classed as being among the top 50 pharma companies when it comes to commercial sales. In 2016, AstraZeneca sold its antibiotics division to Pfizer in a deal worth over $500 million so it could focus on its three main therapy areas of respiratory & autoimmunity, cardiovascular & metabolic diseases, and oncology. Since then, the likes of Novartis, Sanofi and Allergen have exited the space to focus on disease areas which offer better return on investment (ROI). The space then is dominated by smaller biotech companies, and with fewer resources than the major players, the market can be a volatile one to enter. Biotech Achaogen gained regulatory approval from the FDA for its antibiotic plazomicin back in June 2018. Achaogen’s antibiotic was designed to treat complicated urinary tract infections (UTIs) caused by multidrug-resistant Enterobacteriaceae – a pathogen which is of critical priority for new antibiotics according to the WHO. However, a year later Achaogen was declaring bankruptcy and auctioning off its assets. It’s a story that has sadly been repeated by similar companies over the years and it’s a trend which points to one culprit as the catalyst. The Market Anyone following the discourse on antibiotics will know that for some time, pharmaceutical companies have been put off by the lack of ROI for developing new antibiotics. For instance, the Review on Antimicrobial Resistance chaired by Lord Jim O’Neill in 2014, shows that on average, it takes pharmaceutical companies 23 years to start achieving profitability for antibiotics. Then there’s the looming threat of the patent life for antibiotics, or indeed any drug. When a new antibiotic launches onto the market, clinicians may be wary of using it lest resistance begins to develop. During this time, cheaper, generic antibiotics that still work against infections will be used instead. Indeed, the Review on Antimicrobial Resistance report states that whilst the total market for antibiotics is relatively large at $40 billion sales a year, only $4.7 billion of these sales come from patented antibiotics. Compare this to oncology drugs for instance, which are used as first-line treatments once they reach the market and can make massive profits, and it’s understandable why pharma companies choose to invest elsewhere. Next steps With pharmaceutical developers put off from investing in new antibiotics, there is an obvious need for new solutions to incentivise the market so that new innovations can emerge. For that to happen though, there needs be more interest put into the science underpinning antibiotic research – microbiology. Lloyd Czaplewski, Chemical Biology Ventures’ director and someone who was on the advisory group for the WHO’s latest report sees the deficit of microbiologists as a major obstacle to antibiotic development. “When I got into this space 20 years, most major pharma would have a team of 100 or 200 people working in the space – it’s all gone. That size and shape of team doesn’t exist in any one organisation any longer,” he tells me over a phone interview. This has left antibiotic development work up to academics and a selection of biotechs, who don’t have a large enough portfolio to survive when a project fails. “We don’t have the hundreds of people or thousands working in that space that we probably need for training, for career development, for longevity. Because you need to make fundamental discoveries to turn into new products. We don’t have enough of that,” Czaplewski adds. It makes sense that there’s a deficit of microbiologist and infectious disease specialists. The Review on Antimicrobial Resistance highlights that in 2012, doctors in the US working in infectious diseases and HIV were the lowest paid compared to other medical fields. Move to 2021, and data from the National Residents Matching Program showed that 12% of infectious disease trainee positions in the US remain empty. For comparison, there were no positions left unfilled for oncology or pulmonary diseases in 2021.